Shares of Sellas Life Sciences (SLS) jumped 10.8% to $11.09 on August 7, rebounding sharply from a late-July pullback, as investors piled in ahead of what may be the most consequential moment in the company's history: the final data readout from its late-stage blood-cancer drug trial. A broader risk-on rally in U.S. equities added fuel.
The Trial That Will Make or Break the Company
The pivotal Phase 3 REGAL trial has reached 78 of 80 required events, which will trigger the final analysis. The study tests whether Sellas's lead cancer treatment can extend survival for patients with acute myeloid leukemia (AML) who have entered a second remission. CEO Angelos Stergiou confirmed the company is "approaching the pre-specified 80th event threshold" and has entered a quiet period on trial updates.
Earlier company data showed median survival of over 13.5 months in the trial versus a historical median of 6 months for conventional therapy. If the final results confirm that advantage, Sellas could file for FDA approval. If they don't, the stock faces a severe downside given the company has zero approved products and no revenue.
Institutional Money Is Moving In — But From a Low Base
Institutional ownership has doubled to roughly 36.34%, with average allocation rising as both new and existing holders increased stakes ahead of the binary event.
Top holders now include BlackRock (12.2M shares, 11.19%), Vanguard (8.47M shares, 7.81%), and State Street (8.4M shares, 7.70%). That's meaningful validation, but passive and index-linked funds now dominate the shareholder register — meaning much of the buying is mechanical, not a conviction call on the science.
A $138 Million Cash Cushion Buys Time, Not Certainty
Sellas holds an estimated $138.3 million in cash, providing a multi-year runway post-readout.
Expenses are climbing due to manufacturing costs and regulatory consulting in preparation for a potential FDA application. Meanwhile, investors face dilution risk from a $150 million at-the-market stock offering facility the company has in place.
A Wall Street Bull and a Prominent Bear
Alliance Global recently raised its price target to $25 from $10 and reaffirmed a Buy rating. But prominent biotech investor Martin Shkreli remains "very bearish," stating flatly: "it will fail."
The math is simple: everything hinges on the 80th event and the data that follows. Until then, SLS is a high-stakes wager dressed as a stock.